This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effective treatment of over-the-counter medicines: A Synthesis of Findings from 87 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effective treatment of over-the-counter medicines: A Synthesis of Findings from 87 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to Dataset
Please check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

There is no clear consensus regarding systemic treatment of early-stage ovarian cancer (OC). Clinical trials are challenging because of the relatively low incidence and good prognosis. Initial results of the International Collaborative Ovarian Neoplasm (ICON) 1 trial demonstrated benefit in both overall survival (OS) and recurrence-free survival (RFS) with adjuvant chemotherapy. 56

The review highlights that an improved understanding of the molecular basis of ovarian cancer has led to the development of novel agents that work differently from conventional chemotherapy. These include DNA-repair pathway inhibitors, the most common of which are PARP (poly (ADP-ribose) polymerase) inhibitors. 37

This is a short version of a report that presents a comprehensive analysis of clinical trials and publications examining the value of cytotoxic chemotherapy in the treatment of advanced epithelial cancer. The analysis and comments from hundreds of oncologists show that, apart from lung cancer (especially small-cell lung cancer), there is no direct evidence that chemotherapy prolongs survival in patients with advanced carcinoma. Except for ovarian cancer, available indirect evidence rather supports the absence of a positive effect. In the treatment of lung cancer and ovarian cancer, the therapeutic benefit is at best rather small, and a less aggressive treatment seems to be at least as effective as the usual one. It is possible that certain subgroups of patients benefit from the treatment, but the available results do not allow for a sufficiently precise definition of these groups. Many oncologists take it for granted that response to therapy prolongs survival, an opinion based on a fallacy and not supported by clinical studies. To date, it is unclear whether the treated patients, as a whole, benefit from chemotherapy in terms of their quality of life. For most cancer sites, urgently required types of studies such as randomized de-escalations of dose or comparisons of immediate versus deferred chemotherapy are still lacking. With few exceptions, there is no good scientific basis for the application of chemotherapy in symptom-free patients with advanced epithelial malignancy. 4

This systematic literature review investigates the factors that determine surgical success in the treatment of epithelial ovarian cancer. Ovarian cancer is the most lethal gynecological cancer. Progression-free and overall survival are significantly related to surgical success and residual disease volume. It is unclear whether this survival advantage is due to an intrinsic biological element of the tumor cells that enables successful surgery and improved prognosis, or alternatively the number of tumor-sustaining cells remaining irrespective of differences in biology. 48

This is an updated Cochrane review that evaluates the role of adjuvant chemotherapy after surgery for early-stage epithelial ovarian cancer. Epithelial ovarian cancer is diagnosed in over 200,000 women worldwide each year. Ten to 20% of women are diagnosed early, when there is still a good possibility of cure. The treatment of early-stage (stage I and IIa) disease involves surgery to remove the disease, often followed by chemotherapy (adjuvant chemotherapy). The largest clinical trials of adjuvant chemotherapy show an overall survival (OS) advantage with platinum-based chemotherapy; however, the precise role and type of this treatment in subgroups of women with differing prognoses needs to be defined. 62

This review aims to compare the toxicities of different chemotherapy regimens in the treatment of advanced ovarian cancer (AOC) using network meta-analysis. Ovarian cancer (OC) is the 5th leading cause of cancer-related deaths around the world, and several chemotherapy regimens have been applied in the treatment of OC.

Treatment Summary

In the treatment of advanced ovarian cancer, a combination of surgery and chemotherapy is generally considered the most effective approach. Traditionally, surgery is performed first, followed by chemotherapy. However, research suggests that there may be benefits to using chemotherapy before surgery. 75 Additionally, 51 highlights the importance of optimal cytoreductive surgery, which involves removing as much of the tumor as possible during surgery. The less residual tumor left behind, the better the survival rate tends to be.

Treatment for early-stage ovarian cancer (stage I and IIa) often involves surgery to remove the disease, followed by adjuvant chemotherapy. The largest clinical trials of adjuvant chemotherapy have shown an overall survival (OS) advantage with platinum-based chemotherapy. 62 However, more research is needed to determine the precise role and type of adjuvant chemotherapy for subgroups of patients with differing prognoses.

Benefits and Risks

Benefits Summary

In early-stage ovarian cancer, adjuvant chemotherapy can potentially extend overall survival (OS) and recurrence-free survival (RFS). 56 For advanced ovarian cancer, optimal cytoreductive surgery, which aims to remove as much of the tumor as possible, is crucial. 51 Less residual tumor after surgery is associated with a better prognosis.

Risks Summary

Chemotherapy can cause side effects, which vary depending on the drugs used and the dosage. Common side effects include nausea, vomiting, hair loss, fatigue, and bone marrow suppression. 4

Comparison Between Studies

Similarities Between Studies

Many studies agree that a combination of surgery and chemotherapy is effective in treating advanced ovarian cancer. There is also a common understanding that surgery combined with adjuvant chemotherapy is beneficial for treating early-stage ovarian cancer.

Differences Between Studies

There is some variation in findings regarding the optimal chemotherapy regimen for early-stage ovarian cancer. 56 Additionally, research opinions differ on whether surgery first followed by chemotherapy or chemotherapy first followed by surgery is more effective for treating advanced ovarian cancer. 75

Consistency and Contradictions in Results

Current research findings are not entirely consistent when it comes to the optimal chemotherapy regimen for early-stage ovarian cancer. There is also no definitive answer regarding whether surgery first or chemotherapy first is more effective in treating advanced ovarian cancer.

Implications for Real-Life Applications: Important Considerations

Ovarian cancer treatment is individualized and depends on the patient's condition and disease stage. It is essential to consult with your doctor to discuss your situation and choose the most suitable treatment. Chemotherapy can cause side effects, so follow your doctor's instructions and report any side effects promptly.

Limitations of Current Research

Research on ovarian cancer treatment is still ongoing and needs further development. In particular, more research is needed to determine the optimal chemotherapy regimen for early-stage ovarian cancer and whether surgery first or chemotherapy first is more effective in treating advanced ovarian cancer.

Future Research Directions

Future research on ovarian cancer treatment should focus on identifying the optimal chemotherapy regimen for early-stage disease and clarifying the most effective approach for treating advanced disease—surgery first or chemotherapy first. Additionally, research efforts should concentrate on developing new therapies and implementing personalized medicine strategies to further improve ovarian cancer treatment.

Conclusion

While advancements have been made in ovarian cancer treatment, further progress is needed. Surgery combined with adjuvant chemotherapy is generally considered effective for early-stage ovarian cancer, but more research is required to determine the best chemotherapy regimens. A combination of surgery and chemotherapy is generally deemed the most effective approach for treating advanced ovarian cancer, but the optimal sequence—surgery first or chemotherapy first—remains unclear. Research on ovarian cancer treatment is ongoing, and further studies are necessary to develop more effective therapies.

Early detection of ovarian cancer is challenging. Therefore, regular checkups and early detection efforts are crucial. It is also important to be informed about ovarian cancer symptoms and risk factors to increase the chances of early detection. Research on ovarian cancer treatment is continually evolving. Staying informed about the latest treatment advancements and actively engaging in treatment can lead to better outcomes.

Treatment Keywords

Surgery, Chemotherapy, Platinum-based chemotherapy, Adjuvant chemotherapy, Cytoreductive surgery, DNA repair pathway inhibitors, PARP (poly (ADP-ribose) polymerase) inhibitors, Taxane-based chemotherapy, Gemcitabine, Topotecan, Etoposide, Bevacizumab, Hyperthermic intraperitoneal chemotherapy


Keywords
Benefit Keywords
Risk Keywords
Literature analysis of 87 papers
Positive Content
83
Neutral Content
3
Negative Content
1
Article Type
29
27
52
47
87

Language : English


Language : German


Language : English


Language : English


Language : English


Language : English


Language : English


Language : German


Language : English


Language : English


Language : English


Language : English


Language : Russian


Language : German


Language : English


Language : German


Language : Japanese


Language : English


Language : English


Language : German


Language : English


Language : English


Language : English


Language : English


Language : English


Language : Norwegian


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : French


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Author: HarterPhilipp, SehouliJalid, VergoteIgnace, FerronGwenael, ReussAlexander, MeierWerner, GreggiStefano, MosgaardBerit J, SelleFrederic, GuyonFrédéric, PomelChristophe, LécuruFabrice, ZangRongyu, Avall-LundqvistElisabeth, KimJae-Weon, PonceJordi, RaspagliesiFrancesco, KristensenGunnar, ClasseJean-Marc, HillemannsPeter, JensenPernille, HasenburgAnnette, Ghaem-MaghamiSadaf, MirzaMansoor R, LundBente, ReinthallerAlexander, SantaballaAna, OlaitanAdeola, HilpertFelix, du BoisAndreas,


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


Language : English


This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.